Changchun BCHT Biotechnology Co.

Shanghai Stock Exchange 688276.SS

Changchun BCHT Biotechnology Co. Total Assets for the year ending December 31, 2023: USD 710.76 M

Changchun BCHT Biotechnology Co. Total Assets is USD 710.76 M for the year ending December 31, 2023, a 14.50% change year over year. Total assets are the total value of all assets owned by a company, representing its resources.

Changchun BCHT Biotechnology Co. Total Assets for the year ending December 31, 2022 was USD 620.73 M, a -5.52% change year over year.
Changchun BCHT Biotechnology Co. Total Assets for the year ending December 31, 2021 was USD 657.00 M, a 73.80% change year over year.
Changchun BCHT Biotechnology Co. Total Assets for the year ending December 31, 2020 was USD 378.02 M, a 66.26% change year over year.
Changchun BCHT Biotechnology Co. Total Assets for the year ending December 31, 2019 was USD 227.37 M, a 10.88% change year over year.

Key data

Date	Total Assets	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity

Shanghai Stock Exchange: 688276.SS

Changchun BCHT Biotechnology Co.

CEO	Mr. Wei Kong
IPO Date	June 25, 2021
Location	China
Headquarters	1260 Huoju Road
Employees	1,241
Sector	Healthcare
Industries Vaccines Biotechnology Pharmaceuticals

Description

Changchun BCHT Biotechnology Co. Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of human vaccines in China and internationally. Its products include live herpes zoster vaccine; live varicella vaccine; live, nasal, and freeze-dried influenza vaccine; and Rabies vaccine (vero cell) for humans. The company was founded in 2004 and is based in Changchun, China.

Key trends

Past 5 years